CLICK HERE to learn more about Kineta's reverse merger with NASDAQ listed Yumanity Therapeutics (YMTX) and registration statement on Form S-4 with the U.S. SEC

About Us

About Us

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.

Since our inception, our focus has been targeting novel innate immune pathways where the biology had not yet translated into innovative therapies.   We have leveraged our expertise in innate immunity to discover and develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. One of Kineta’s key competitive advantages was building a strong foundation with an industry-leading scientific team who drive our research and development engine bolstered by an exceptional immuno-oncology focused scientific advisory board.  We have integrated strong commercial leadership with our research and development team to enable Kineta to advance multiple drug programs in areas with high unmet needs and significant commercial potential.

“We aim to improve outcomes
for cancer patients
through our scientific innovation.”

                                           Shawn Iadonato — Kineta CEO

Leadership Team

Kineta is led by a team with diverse talents who are recognized for their expertise in drug development, corporate finance and success in bringing new pharmaceutical therapies to market.

Shawn Iadonato 21 – Mgmt

Shawn Iadonato, PhD

Chief Executive Officer

Craig Phillips 21

Craig Philips


Pauline Kenny 21

Pauline Kenny, JD

General Counsel

Thierry Guillaudeux, PhD 21

Thierry Guillaudeux, PhD

Chief Scientific Officer

Jacques Bouchy 21

Jacques Bouchy

SVP Business Development & Corporate Communications

Molly Dorr 21

Molly Dorr

Head of Human Resources & Operations

Chanya Swartz 21

Chanya Swartz

Sr. Director Finance & Corporate Controller

Sang-Seon Yun 21

Sang Seon Yun, PhD

Head of Scientific Affairs

Board of Directors

Scientific Advisory Board